Literature DB >> 34907529

Structure-based survey of ligand binding in the human insulin receptor.

Lokender Kumar1, Whitney Vizgaudis2, Judith Klein-Seetharaman2,3.   

Abstract

The insulin receptor is a membrane protein responsible for the regulation of nutrient balance; and therefore, it is an attractive target in the treatment of diabetes and metabolic syndrome. Pharmacology of the insulin receptor involves two distinct mechanisms: (1) activation of the receptor by insulin mimetics that bind in the extracellular domain and (2) inhibition of the receptor TK enzymatic activity in the cytoplasmic domain. While a complete structural picture of the full-length receptor comprising the entire sequence covering extracellular, transmembrane, juxtamembrane and cytoplasmic domains is still elusive, recent progress through cryoelectron microscopy has made it possible to describe the initial insulin ligand binding events at atomistic detail. We utilize this opportunity to obtain structural insights into the pharmacology of the insulin receptor. To this end, we conducted a comprehensive docking study of known ligands to the new structures of the receptor. Through this approach, we provide an in-depth, structure-based review of human insulin receptor pharmacology in light of the new structures. LINKED ARTICLES: This article is part of a themed issue on Structure Guided Pharmacology of Membrane Proteins (BJP 75th Anniversary). To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v179.14/issuetoc.
© 2021 The British Pharmacological Society.

Entities:  

Keywords:  insulin; membrane receptor; molecular docking; protein structure-function; signal transduction

Mesh:

Substances:

Year:  2022        PMID: 34907529     DOI: 10.1111/bph.15777

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   9.473


  1 in total

1.  Targeting the cell's gatekeepers for novel drug discovery.

Authors:  Gary J Stephens; Arun K Shukla
Journal:  Br J Pharmacol       Date:  2022-04-07       Impact factor: 9.473

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.